NU12 behaved as a sunitinib ‘sensitive’ tumor: in vivo sunitinib treatment led to massive necrosis and decreased MVD and concomitantly accumulation of monoclonal antibody cG250, specific for CAIX which is highly expressed on ccRCC, was markedly reduced. This evidence concerns the gene CA9 and nonpapillary renal cell carcinoma.